NCT03193099 (Win-HD) is a NA clinical trial of Brain imaging in Huntington Disease, sponsored by Institut National de la Santé Et de la Recherche Médicale, France.

Who is sponsoring NCT03193099?

NCT03193099 is sponsored by Institut National de la Santé Et de la Recherche Médicale, France.

What drugs are being tested in NCT03193099?

Interventions in NCT03193099: Brain imaging, Neurological assessments, Psychological assessments, Behavioural assessments.

What condition does NCT03193099 study?

NCT03193099 studies Huntington Disease, White Matter Alterations.

Is NCT03193099 still recruiting?

NCT03193099 is currently completed. Last updated 18 February 2020.

Last reviewed 2020-02-18 · How we verify

NCT03193099: Win-HD

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Decoding Presymptomatic White Matter Changes in Huntington Disease

Completed NA Last updated 18 February 2020

What this trial tests

NA trial testing Brain imaging in Huntington Disease in 60 participants. Completed in 30 December 2019.

Timeline

11 July 2017

Primary endpoint
30 December 2019

30 December 2019

Quick facts

Lead sponsor	Institut National de la Santé Et de la Recherche Médicale, France
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	other
Enrollment	60
Start date	11 July 2017
Primary completion	30 December 2019
Estimated completion	30 December 2019
Sites	1 location across France

Drugs / interventions tested

Brain imaging
Neurological assessments
Psychological assessments
Behavioural assessments

Conditions studied

Huntington Disease — all drugs for Huntington Disease →
White Matter Alterations — all drugs for White Matter Alterations →

Sponsor

Institut National de la Santé Et de la Recherche Médicale, France — full company profile →

Who can join

18 and older, any sex, with Huntington Disease or White Matter Alterations. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

WIN-HD is a monocentric longitudinal study comparing premanifest Huntingtin (HTT) mutation carriers and non HTT mutation carriers to determine that white-matter atrophy occurs far earlier than clinical onset in HD using Diffusion-weighted Nuclear Magnetic Resonance (N spectroscopy (DWS) and Diffusion Tensor Imaging (DTI). The investigators will recruit up to 20 premanifest HTT mutation carriers (15 completed) and up to 20 non HTT mutation carriers (15 completed). It is important to have those 2 populations in order to compare our results and determine if there are significant white-matter changes far from the onset of HD. Therefore, non HTT mutation carriers will be age and gender matched to premanifest HTT mutation carriers. In order to test the hypothesis, the study has 2 visits with a year interval. This study is based on 4 principal criteria: 1. Imaging criteria 2. Clinical and neurological criteria 3. Psychological criteria 4. Behavioral criteria

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Brain imaging

Trials testing the same drug.

NCT06866379 — Involvement of the Septal Nuclei of the Human Brain in Alcohol Use Disorder · NA · recruiting
NCT06247449 — MRI Screening for Brain Metastases Among Patients With Triple Negative or HER2+ Stage II or III Breast Cancer · NA · recruiting
NCT05119023 — Determining Learning Ability in People With Aphasia · NA · completed
NCT05216770 — Understanding Disorder-specific Neural Pathophysiology in Laryngeal Dystonia and Voice Tremor · EARLY_PHASE1 · recruiting

Other recruiting trials for Huntington Disease

Currently open trials in the same condition.

NCT07326709 — A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease · Phase 3 · recruiting
NCT07253038 — Evaluation of Three Tests to Assess Social Cognition in Huntington Disease · recruiting
NCT06774443 — Hinting Task for Huntington's Disease · recruiting
NCT06546488 — Cognitive Assessment Tools for Huntington's Disease. · recruiting
NCT07010705 — Digital Measures for Clinical Trial Endpoints in Huntington's Disease · recruiting

Other Institut National de la Santé Et de la Recherche Médicale, France trials

Trials by the same sponsor.

NCT07311213 — GENES AND AUTISM - IPSC · NA · not yet recruiting
NCT07063719 — Identification of Cellular Biomarkers of Rare Eye Diseases in Adults · NA · not yet recruiting
NCT06906042 — Multimodal Cardiovascular and Hepatic Population Imaging · recruiting
NCT06951035 — Impact of rTMS on BCI Control in Upper Limb Motor Rehabilitation of Patients With Chronic Stroke · NA · not yet recruiting
NCT06660108 — MOLECULAR BASIS OF LANGUAGE DEVELOPMENT AND ASSOCIATED DISORDERS · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03193099 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Institut National de la Santé Et de la Recherche Médicale, France
Last refreshed: 18 February 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03193099.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing